RNAi targeting embryonic myosin heavy chain isoform inhibited bound thrombin-induced migration of vascular smooth muscle cells

Journal of Vascular Research

Volumn 46, Issue 1, 2008, Pages 55-63

  Sunagawa, Masanori ^a   Shimada, Seiji ^a   Nakamura, Mariko ^a   Kosugi, Tadayoshi ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Bound thrombin; Cultured vascular smooth muscle cells; Migration; siRNA; SMemb gene

Indexed keywords

FIBRIN; MESSENGER RNA; MYOSIN HEAVY CHAIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN SMEMB; SMALL INTERFERING RNA; THROMBIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; NONHUMAN; NORTHERN BLOTTING; OPEN READING FRAME; PRIORITY JOURNAL; RNA INTERFERENCE; VASCULAR SMOOTH MUSCLE;

ANIMALS; CELL MOVEMENT; CELLS, CULTURED; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; MYOSIN HEAVY CHAINS; PROTEIN ISOFORMS; RABBITS; RNA INTERFERENCE; THROMBIN;

EID: 57449110417     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000139133     Document Type: Article

References (28)

1. Kastrati A, Schomig A, Elezi S, Dirschinger J, Mehilli J, Schuhlen H, Blasini R, Neumann FJ: Prognostic value of the modified American College of Cardiology/American Heart Association stenosis morphology classification for long-term angiographic and clinical outcome after coronary stent placement. Circulation 1999;100:1285-1290.
2. Radke PW, Klues HG, Haager PK, Hoffmann R, Kastrau F, Reffelmann T, Janssens U, vom Dahl J, Hanrath P: Mechanisms of acute lumen gain and recurrent restenosis after rotational atherectomy of diffuse in-stent restenosis: a quantitative angiographic and intravascular ultrasound study. J Am Coll Cardiol 1999;34:33-39.
3. Schofer J, Rau T, Schluter M, Mathey DG: Short-term results and intermediate-term follow-up of laser wire recanalization of chronic coronary artery occlusions: a single-center experience. J Am Coll Cardiol 1997;30:1722-1728.
4. Kuro-o M, Nagai R, Nakahara K, Katoh H, Tsai RC, Tsuchimochi H, Yazaki Y, Ohkubo A, Takaku F: cDNA cloning of a myosin heavy chain isoform in embryonic smooth muscle and its expression during vascular development and in arteriosclerosis. J Biol Chem 1991;266:3768-3773.
5. Francis CW, Markham RE Jr, Barlow GH, Florack TM, Dobrzynski DM, Marder VJ: Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med 1983;102:220-230.
6. Oltrona L, Eisenberg PR, Lasala JM, Sewall DJ, Shelton ME, Winters KJ: Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions. Circulation 1996;94:2064-2071.
7. Reganon E, Ferrando F, Vila V, Villa P, Martinez-Sales V, Fayos L, Ruano M, Aznar J: Increase in thrombin generation after coronary thrombolysis with rt-PA or streptokinase with simultaneous heparin versus heparin alone. Haemostasis 1998;28:99-105.
8. Becker DL, Fredenburgh JC, Stafford AR, Weitz JI: Molecular basis for the resistance of fibrin-bound thrombin to inactivation by heparin/serpin complexes. Adv Exp Med Biol 1997;425:55-66.
9. Weitz JI, Leslie B, Hudoba M: Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 1998;97:544-552.
10. Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP: Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest 1993;91:1877-1883.
11. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J: Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-391.
12. Ip JH, Fuster V, Israel D, Badimon L, Badimon J, Chesebro JH: The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty. J Am Coll Cardiol 1991;17:77B-88B.
13. Moons AH, Levi M, Peters RJ: Tissue factor and coronary artery disease. Cardiovasc Res 2002;53:313-325.
14. Kinjoh K, Nakamura M, Sunagawa M, Kosugi T: Isolation of bound thrombin consisting of thrombin and fibrin N-terminal fragments from clot lysate. Haematologia (Budap) 2002;32:457-465.
15. Kinjoh K, Nakamura M, Zeng G, Sunagawa M, Eguchi Y, Kosugi T: Bound thrombin from crushed clots was composed of a-thrombin and N-terminal regions of a and g chains of fibrinogen. Pathophysiol Haemost Thromb 2002;32:165-173.
16. Zeng G, Kinjoh K, Nakamura M, Kosugi T: The activity of postclotting thrombins on platelet activation was identical to that of native thrombin. J Jap Coll Angiol 2002;42:25-31.
17. Shimada S, Sunagawa M, Nakamura M, Kosugi T: Bound thrombin-induced upregulation of myosin heavy chain isoform, SMemb messenger RNA expression in cultured rabbit vascular smooth muscle cells. Int J Tissue React 2003;25:137-148.
18. Shimada S, Sunagawa M, Hanashiro K, Nakamura M, Kosugi T: RNA interference targeting embryonic myosin heavy chain isoform inhibited mRNA expressions of phenotype markers in rabbit cultured vascular smooth muscle cells. Heart Vessels 2007;22:41-47.
19. Yoshinaga M, Sunagawa M, Shimada S, Nakamura M, Murayama S, Kosugi T: Argatroban, specific thrombin inhibitor, induced phenotype change of cultured rabbit vascular smooth muscle cells. Eur J Pharmacol 2003;461:9-17.
20. Nakamura M, Kinjoh K, Hanashiro K, Tokeshi Y, Sunagawa M, Kosugi T: The bound-thrombin was uncompetitivey inhibited by argatroban. Br J Haematol 1998;102:138-139.
21. 2+ channel current in cultured vascular smooth muscle cells. Am J Physiol Cell Physiol 2000;279:C480-C487.
22. Rovner AS, Thompson MM, Murphy RA: Two different heavy chains are found in smooth muscle myosin. Am J Physiol 1986;250:C861-C870.
23. Al-Fakhri N, Chavakis T, Schmidt-Woll T, Huang B, Cherian SM, Bobryshev YV, Lord RS, Katz N, Preissner KT: Induction of apoptosis in vascular cells by plasminogen activator inhibitor-1 and high molecular weight kininogen correlates with their anti-adhesive properties. Biol Chem 2003;384:423-435.
24. Bornfeldt KE, Raines EW, Nakano T, Graves LM, Krebs EG, Ross R: Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest 1994;93:1266-1274.
25. Pauly RR, Bilato C, Sollott SJ, Monticone R, Kelly PT, Lakatta EG, Crow MT: Role of calcium/calmodulin-dependent protein kinase II in the regulation of vascular smooth muscle cell migration. Circulation 1995;91:1107-1115.
26. Hynes RO: Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25.
27. Katsuda S, Okada Y: Vascular smooth muscle cell migration and extracellular matrix. J Atheroscler Thromb 1994;1(suppl 1):S34-S38.
28. Stefansson S, McMahon GA, Petitclerc E, Lawrence DA: Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des 2003;9:1545-1564.